AGIOS PHARMACEUTICALS, INC. Finance Lease, Principal Payments
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Finance Lease, Principal Payments of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:FinanceLeasePrincipalPayments · last filed 2025-02-13
- AGIOS PHARMACEUTICALS, INC. finance lease, principal payments for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. finance lease, principal payments for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. finance lease, principal payments for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. finance lease, principal payments for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. finance lease, principal payments for fiscal 2024 was $0.00.
- AGIOS PHARMACEUTICALS, INC. finance lease, principal payments for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- AGIOS PHARMACEUTICALS, INC. finance lease, principal payments for fiscal 2022 was $331.00K, a 42.73% decline from fiscal 2021.
- AGIOS PHARMACEUTICALS, INC. finance lease, principal payments for fiscal 2021 was $578.00K, a 72.02% increase from fiscal 2020.
| Period end | Finance Lease, Principal Payments 3 month | Finance Lease, Principal Payments 6 month | Finance Lease, Principal Payments 9 month | Finance Lease, Principal Payments 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-13 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $0.00 derived: sum of 2 quarters · filed 2025-02-13 | $0.00 derived: sum of 3 quarters · filed 2025-02-13 | $0.00 10-K · filed 2025-02-13 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | $83.00K derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | $83.00K derived: sum of 3 quarters · filed 2025-02-13 | $167.00K derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | $83.00K derived: sum of 2 quarters · filed 2025-02-13 | $167.00K derived: sum of 3 quarters · filed 2025-02-13 | $250.00K derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | $83.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $167.00K derived: sum of 2 quarters · filed 2025-02-13 | $250.00K derived: sum of 3 quarters · filed 2025-02-13 | $331.00K 10-K · filed 2025-02-13 |
| 2022-09-30 | $84.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $167.00K derived: sum of 2 quarters · filed 2023-11-02 | $248.00K 10-Q · filed 2023-11-02 | $53.00K derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $83.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $164.00K 10-Q · filed 2023-08-03 | -$31.00K derived: sum of 3 quarters · filed 2024-02-15 | $572.00K derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $81.00K 10-Q · filed 2023-05-04 | -$114.00K derived: sum of 2 quarters · filed 2024-02-15 | $489.00K derived: sum of 3 quarters · filed 2024-02-15 | $573.00K derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | -$195.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $408.00K derived: sum of 2 quarters · filed 2024-02-15 | $492.00K derived: sum of 3 quarters · filed 2024-02-15 | $578.00K 10-K · filed 2024-02-15 |
| 2021-09-30 | $603.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $687.00K derived: sum of 2 quarters · filed 2022-11-03 | $773.00K 10-Q · filed 2022-11-03 | $859.00K derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $84.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $170.00K 10-Q · filed 2022-08-04 | $256.00K derived: sum of 3 quarters · filed 2023-02-23 | $340.00K derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $86.00K 10-Q · filed 2022-05-05 | $172.00K derived: sum of 2 quarters · filed 2023-02-23 | $256.00K derived: sum of 3 quarters · filed 2023-02-23 | $342.00K derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $86.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $170.00K derived: sum of 2 quarters · filed 2023-02-23 | $256.00K derived: sum of 3 quarters · filed 2023-02-23 | $336.00K 10-K · filed 2023-02-23 |
| 2020-09-30 | $84.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $170.00K derived: sum of 2 quarters · filed 2021-11-03 | $250.00K 10-Q · filed 2021-11-03 | $363.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $86.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $166.00K 10-Q · filed 2021-07-29 | $279.00K derived: sum of 3 quarters · filed 2022-02-24 | $279.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $80.00K 10-Q · filed 2021-04-29 | $193.00K derived: sum of 2 quarters · filed 2022-02-24 | $193.00K derived: sum of 3 quarters · filed 2022-02-24 | $193.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $113.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $113.00K derived: sum of 2 quarters · filed 2022-02-24 | $113.00K derived: sum of 3 quarters · filed 2022-02-24 | $113.00K 10-K · filed 2022-02-24 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $0.00 10-Q · filed 2020-07-30 | ||
| 2019-03-31 | $0.00 10-Q · filed 2020-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |